Pulmonary Disease Caused by Non-Tuberculous Mycobacteria
Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are parti...
Gespeichert in:
| Veröffentlicht in: | Respiration Jg. 91; H. 5; S. 386 - 402 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Basel, Switzerland
S. Karger AG
01.01.2016
Karger |
| Schlagworte: | |
| ISSN: | 0025-7931, 1423-0356, 1423-0356 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease. |
|---|---|
| AbstractList | Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease. Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease.Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease. Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease. (C) 2016 S. Karger AG, Basel Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to NTM pulmonary disease, many affected patients have no apparent risk factors. Host and pathogen factors leading to NTM pulmonary disease are not well understood and preventive therapies are lacking. NTM isolation and pulmonary disease are reported to rise in frequency in Europe as well as in other parts of the world. Differentiation between contamination, infection, and disease remains challenging. Treatment of NTM pulmonary disease is arduous, lengthy, and costly. Correlations between results of in vitro antibiotic susceptibility testing and clinical treatment outcomes are only evident for the Mycobacterium avium complex, M. kansasii, and some rapidly growing mycobacteria. We describe the epidemiology of NTM pulmonary disease as well as emerging NTM pathogens and their geographical distribution in non-cystic fibrosis patients in Europe. We also review recent innovations for the diagnosis of NTM pulmonary disease, summarize treatment recommendations, and identify future research priorities to improve the management of patients affected by NTM pulmonary disease. Keywords: Europe, Mycobacterium, Mycobacterium avium/intracellulare complex, Non-tuberculous mycobacteria, Pulmonary disease |
| Audience | Academic |
| Author | Andrejak, Claire Wassilew, Nasstasja Hoffmann, Harald Lange, Christoph |
| Author_xml | – sequence: 1 givenname: Nasstasja surname: Wassilew fullname: Wassilew, Nasstasja – sequence: 2 givenname: Harald surname: Hoffmann fullname: Hoffmann, Harald – sequence: 3 givenname: Claire surname: Andrejak fullname: Andrejak, Claire – sequence: 4 givenname: Christoph surname: Lange fullname: Lange, Christoph email: clange@fz-borstel.de |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27207809$$D View this record in MEDLINE/PubMed https://u-picardie.hal.science/hal-03591346$$DView record in HAL http://kipublications.ki.se/Default.aspx?queryparsed=id:133767203$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNpt0ctv1DAQB2ALFdFt4cAdoUhICA6h4zh-HVfLo0jL41DOlp1Mu2m98dZOQPvf4yjbRSBOjsaff5rJnJGTPvRIyHMK7yjl-gIA6pprEI_IgtYVK4FxcUIWABUvpWb0lJyldAtAuVLVE3JayQqkAr0g6vvot6G3cV-87xLahMXKjgnbwu2Lr6Evr0aHsRl9GFPxZd8EZ5sBY2efksfX1id8djjPyY-PH65Wl-X626fPq-W6bDhTQ9k6KbgTVFgtK9Yy7bhGsLkzncu2kQ64sJXQDbZcSAZSgFJaoAJUyml2Tso5N_3C3ejMLnbb3K0JtjOH0l3-QsOBQy2yfzv7jfV_4cvl2ky1_G80ZbX4SbN9M9tdDPcjpsFsu9Sg97bHPK-hUkuV26Yq01f_0Nswxj5PbhjUWciqngJfz-rGejQbtH7YpODHoQt9MkvBJJVcqCnu5SFudFtsj40-LCaDixk0MaQU8do03WCnnCHazhsKZlq9Oa7-z-DHFw-h_7MvZntn4w3Gozxc_wa6_rFv |
| CitedBy_id | crossref_primary_10_1159_000449037 crossref_primary_10_1016_j_jfma_2020_05_013 crossref_primary_10_1128_microbiolspec_TNMI7_0011_2016 crossref_primary_10_1099_jmm_0_001809 crossref_primary_10_1097_MD_0000000000025283 crossref_primary_10_1016_j_jgar_2020_04_028 crossref_primary_10_3390_microorganisms8081114 crossref_primary_10_1016_j_rxeng_2023_09_001 crossref_primary_10_3389_fimmu_2021_728742 crossref_primary_10_3389_fpubh_2022_989587 crossref_primary_10_1186_s40249_021_00844_1 crossref_primary_10_21292_2075_1230_2019_97_6_16_22 crossref_primary_10_1016_j_jinf_2021_05_019 crossref_primary_10_1016_j_micres_2024_128039 crossref_primary_10_1177_20499361251331676 crossref_primary_10_3389_fmicb_2021_695024 crossref_primary_10_1007_s13665_019_00237_8 crossref_primary_10_1016_j_bbrc_2023_149249 crossref_primary_10_1016_j_nmni_2017_08_008 crossref_primary_10_3390_antibiotics13050404 crossref_primary_10_1016_j_envpol_2025_126812 crossref_primary_10_1186_s12879_018_3559_x crossref_primary_10_1016_j_ijid_2022_09_031 crossref_primary_10_1016_j_jmii_2020_02_005 crossref_primary_10_1159_000520033 crossref_primary_10_2147_IDR_S388629 crossref_primary_10_1186_s12890_019_0881_z crossref_primary_10_1371_journal_pone_0301659 crossref_primary_10_1136_thorax_2022_219116 crossref_primary_10_1186_s12879_024_09016_6 crossref_primary_10_1136_bcr_2021_246567 crossref_primary_10_3389_fmicb_2018_01471 crossref_primary_10_1111_1440_1681_13651 crossref_primary_10_1016_j_vetmic_2024_110250 crossref_primary_10_3390_microorganisms11010120 crossref_primary_10_1007_s15010_018_1128_2 crossref_primary_10_3389_fmicb_2018_02029 crossref_primary_10_1016_j_resinv_2019_07_001 crossref_primary_10_3389_fcimb_2025_1557079 crossref_primary_10_1080_23744235_2017_1411604 crossref_primary_10_1016_j_jiac_2022_03_026 crossref_primary_10_4103_jgid_jgid_152_24 crossref_primary_10_1089_ees_2021_0272 crossref_primary_10_7759_cureus_86982 crossref_primary_10_4103_ijmy_ijmy_224_21 crossref_primary_10_4103_pulmon_pulmon_10_24 crossref_primary_10_3389_fmicb_2018_02813 crossref_primary_10_3389_fphar_2021_724725 crossref_primary_10_1002_kjm2_12608 crossref_primary_10_1111_os_13661 crossref_primary_10_1016_j_ijmmb_2021_07_005 crossref_primary_10_3389_fcimb_2023_1205225 crossref_primary_10_1177_1066896919879745 crossref_primary_10_1016_j_jgar_2023_08_002 crossref_primary_10_1155_2019_5942783 crossref_primary_10_1371_journal_pone_0168290 crossref_primary_10_1080_17476348_2021_1887734 crossref_primary_10_1080_24745332_2025_2488848 crossref_primary_10_1155_2020_6287545 crossref_primary_10_1016_j_rcl_2022_01_012 crossref_primary_10_3389_fcimb_2023_1253020 crossref_primary_10_1080_17476348_2021_1925545 crossref_primary_10_1093_ofid_ofy034 crossref_primary_10_1007_s00408_020_00414_6 crossref_primary_10_1016_j_diagmicrobio_2022_115756 crossref_primary_10_1371_journal_pntd_0007083 crossref_primary_10_1016_j_jgar_2020_01_004 crossref_primary_10_3390_antibiotics11070873 crossref_primary_10_1016_j_rcl_2022_01_009 crossref_primary_10_3389_fmicb_2024_1331508 crossref_primary_10_1007_s00266_024_04490_4 crossref_primary_10_1007_s10405_022_00485_7 crossref_primary_10_1016_j_bbrc_2023_05_095 crossref_primary_10_3389_fpubh_2022_912651 crossref_primary_10_2147_IDR_S422191 crossref_primary_10_4103_ijmr_IJMR_902_20 crossref_primary_10_1038_s41598_024_64029_0 crossref_primary_10_1080_17460441_2019_1629414 crossref_primary_10_1016_j_jiac_2019_06_013 crossref_primary_10_2478_ahem_2021_0050 crossref_primary_10_33073_pjm_2023_048 crossref_primary_10_4103_ijmy_ijmy_141_21 crossref_primary_10_1016_j_rx_2021_10_002 crossref_primary_10_3389_fimmu_2025_1556683 crossref_primary_10_3389_fpubh_2020_00295 crossref_primary_10_1007_s10123_020_00143_z crossref_primary_10_1093_femsml_uqab013 crossref_primary_10_4103_atm_atm_45_21 crossref_primary_10_7759_cureus_91797 crossref_primary_10_1016_j_ijmm_2019_05_007 crossref_primary_10_1007_s00726_021_03044_1 crossref_primary_10_1590_0074_02760180085 crossref_primary_10_1016_j_micinf_2017_09_005 crossref_primary_10_1097_RCT_0000000000001368 crossref_primary_10_2147_IDR_S529466 crossref_primary_10_1097_MD_0000000000030704 crossref_primary_10_4103_lungindia_lungindia_365_19 crossref_primary_10_1016_j_scitotenv_2020_144552 crossref_primary_10_1093_jacamr_dlab004 crossref_primary_10_1513_AnnalsATS_201804_236OC crossref_primary_10_1371_journal_pntd_0005841 |
| Cites_doi | 10.1016/j.ccm.2014.10.002 10.1128/JCM.05995-11 10.1183/09031936.00039009 10.1136/thx.2005.054908 10.1016/j.drup.2012.04.001 10.1099/ijs.0.63969-0 10.1136/bcr.06.2011.4360 10.1099/ijs.0.010405-0 10.1378/chest.127.2.664 10.1378/chest.124.4.1482 10.1186/1471-2458-10-612 10.1136/thx.2008.110957 10.1007/s00330-001-1282-1 10.1136/thoraxjnl-2015-207360 10.1086/648443 10.1164/rccm.201402-0363PP 10.1164/ajrccm.185.2.231 10.1001/archinte.163.7.845 10.3201/eid1403.061393 10.1513/AnnalsATS.201307-231OC 10.1136/thoraxjnl-2013-204260 10.1093/jac/dkv180 10.1164/rccm.201111-2005OC 10.1136/thoraxjnl-2015-207983 10.1099/ijs.0.008854-0 10.1128/JCM.01612-13 10.1183/09031936.05.00148604 10.1136/thx.2007.087999 10.1128/AEM.68.11.5580-5584.2002 10.1371/journal.pone.0128304 10.1136/thorax.56.3.167 10.1136/thoraxjnl-2012-201772 10.1016/S0140-6736(13)60632-7 10.1093/jac/dks421 10.1378/chest.15-0458 10.1016/j.rmed.2005.08.005 10.1093/jac/dku007 10.1136/thx.2006.070797 10.1128/AAC.38.11.2676 10.1378/chest.115.4.1033 10.1309/AJCPBPUBUDEW2OAG 10.5588/ijtld.14.0140 10.1186/1471-2334-14-62 10.1159/000339631 10.1164/ajrccm.153.6.8665032 10.1016/j.ijantimicag.2009.12.008 10.1016/j.ccm.2014.10.004 10.2217/fmb.14.60 10.1155/2014/894976 10.1164/rccm.201206-1088OC 10.1378/chest.129.2.341 10.1164/rccm.201002-0310OC 10.1164/rccm.201003-0395OC 10.1136/thorax.55.3.210 10.3201/eid1911.130737 10.1183/09031936.00066614 10.1099/mic.0.033522-0 10.1186/1471-2334-14-279 10.1183/09031936.00195009 10.1099/ijs.0.037465-0 10.1186/1471-2334-13-231 10.1183/09031936.00169114 10.1164/rccm.201208-1478ED 10.1128/AAC.01505-12 10.1093/cid/ciq237 10.3978/j.issn.2072-1439.2013.12.24 10.1128/CMR.00020-11 10.1378/chest.13-2538 10.1164/rccm.200905-0704OC 10.1183/09031936.04.00114004 10.5588/ijtld.14.0120 10.1183/09031936.00063806 10.1093/jac/dkr578 10.1378/chest.14-1297 10.1128/AAC.00861-10 10.1080/00365540210147813 10.4997/JRCPE.2011.403 10.1371/journal.pone.0077385 10.1164/rccm.201408-1545OC 10.1128/JCM.02051-08 10.1371/journal.pone.0139621 10.1086/317468 10.1016/j.jiac.2014.05.010 10.1055/s-0033-1344790 10.1053/crad.2001.0851 10.1097/QCO.0000000000000104 10.1164/rccm.200604-571ST 10.1016/S2213-2600(15)00033-8 10.1164/rccm.201001-0077OC 10.1016/j.rmed.2014.10.013 10.1164/rccm.201501-0067OC 10.1513/AnnalsATS.201308-266OC 10.1016/j.rmed.2006.04.002 10.1164/rccm.201204-0682OC 10.1093/clinids/3.5.1035 10.1183/09031936.00149212 10.1186/s12879-015-0823-1 10.1016/j.ccm.2014.11.005 10.1164/rccm.201507-1392LE 10.1128/JCM.01444-08 10.1164/rccm.200905-0778OC 10.1016/j.ccm.2014.10.003 10.1586/14787210.2013.830413 10.1099/ijs.0.023770-0 10.1371/journal.pone.0005660 10.1111/j.1365-2672.2009.04161.x 10.5588/ijtld.12.0843 10.1128/AAC.38.7.1455 10.1136/thx.49.5.442 10.4065/77.11.1233 10.1016/j.mimet.2015.09.010 10.1128/AAC.37.11.2364 10.1128/AAC.47.5.1736-1738.2003 10.1128/JCM.01175-12 10.1016/j.ccm.2014.11.001 10.1001/archsurg.1986.01400070079017 10.1016/j.ccm.2014.10.001 10.1371/journal.pone.0108703 10.1378/chest.14-2764 10.1111/lam.12243 10.1128/JCM.00612-11 10.1016/j.carj.2013.05.006 10.1128/AAC.04577-14 10.3109/00365548.2012.694469 10.1086/517366 10.1016/j.ijantimicag.2013.05.007 10.1007/s00408-004-2508-1 10.1155/2014/371370 |
| ContentType | Journal Article |
| Copyright | 2016 The Author(s) Published by S. Karger AG, Basel 2016 The Author(s) Published by S. Karger AG, Basel. COPYRIGHT 2016 S. Karger AG 2016 The Author(s) Published by S. Karger AG, Basel. This work is licensed under the Creative Commons Attribution – Non-Commercial – No Derivatives License http://creativecommons.org/licenses/by-nc-nd/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2016 The Author(s) Published by S. Karger AG, Basel – notice: 2016 The Author(s) Published by S. Karger AG, Basel. – notice: COPYRIGHT 2016 S. Karger AG – notice: 2016 The Author(s) Published by S. Karger AG, Basel. This work is licensed under the Creative Commons Attribution – Non-Commercial – No Derivatives License http://creativecommons.org/licenses/by-nc-nd/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | M-- AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ U9A 7X8 1XC ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1159/000445906 |
| DatabaseName | Karger Open Access Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Hyper Article en Ligne (HAL) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Career and Technical Education (Alumni Edition) MEDLINE - Academic |
| DatabaseTitleList | CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1423-0356 |
| EndPage | 402 |
| ExternalDocumentID | oai_swepub_ki_se_505046 oai:HAL:hal-03591346v1 A637175688 27207809 10_1159_000445906 445906 |
| Genre | Journal Article Review |
| GeographicLocations | Germany Northern Europe United Kingdom--UK United States--US Europe |
| GeographicLocations_xml | – name: Germany – name: United Kingdom--UK – name: Northern Europe – name: United States--US – name: Europe |
| GroupedDBID | --- .GJ .XZ 0R~ 0~5 0~B 123 29P 30W 327 34G 36B 39C 3O. 3V. 4.4 53G 5RE 7RQ 7RV 7X7 88E 8AO 8FI 8FJ 8G5 8UI AAWTL AAYIC ABJNI ABPAZ ABUWG ACGFS ACPSR ADAGL ADBBV AENEX AEYAO AFJJK AFKRA AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS APPQY AZPMC AZQEC BENPR BKEYQ BPHCQ BVXVI C45 CAG CCPQU COF CS3 CYUIP DU5 DWQXO E0A EBS EJD EMB EMOBN EX3 F5P FB. FYUFA GNUQQ GUQSH HMCUK HZ~ IAO IHR IHW IY7 KUZGX L7B M-- M1P M2O N9A NAPCQ O1H O9- OVD PQQKQ PROAC PSQYO RIG RKO RXVBD SV3 TEORI UJ6 UKHRP WOW ZGI ZXP AAYXX ABBTS ABWCG ACQXL AFFHD AFSIO AHFRZ CITATION ITC PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM K9. U9A 7X8 1XC ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c538t-db765b616a9723d39b59e0a00295b6ac7b056a269ced567307608896e80e88b93 |
| IEDL.DBID | M-- |
| ISICitedReferencesCount | 122 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000377991300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0025-7931 1423-0356 |
| IngestDate | Tue Nov 25 03:35:17 EST 2025 Tue Oct 14 20:11:55 EDT 2025 Thu Oct 02 03:56:49 EDT 2025 Mon Oct 06 18:20:21 EDT 2025 Thu May 22 21:21:14 EDT 2025 Wed Feb 19 02:09:09 EST 2025 Sat Nov 29 07:59:53 EST 2025 Tue Nov 18 21:57:12 EST 2025 Thu Aug 29 12:04:42 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Non-tuberculous mycobacteria Mycobacterium Mycobacterium avium/intracellulare complex Pulmonary disease Europe |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. https://creativecommons.org/licenses/by-nc-nd/4.0 2016 The Author(s) Published by S. Karger AG, Basel. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c538t-db765b616a9723d39b59e0a00295b6ac7b056a269ced567307608896e80e88b93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-9691-4741 0000-0002-9998-8578 |
| OpenAccessLink | https://karger.com/doi/10.1159/000445906 |
| PMID | 27207809 |
| PQID | 3043187241 |
| PQPubID | 41084 |
| PageCount | 17 |
| ParticipantIDs | crossref_citationtrail_10_1159_000445906 hal_primary_oai_HAL_hal_03591346v1 crossref_primary_10_1159_000445906 proquest_journals_3043187241 proquest_miscellaneous_1797872318 pubmed_primary_27207809 swepub_primary_oai_swepub_ki_se_505046 gale_healthsolutions_A637175688 karger_primary_445906 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-01 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland – name: Basel |
| PublicationTitle | Respiration |
| PublicationTitleAlternate | Respiration |
| PublicationYear | 2016 |
| Publisher | S. Karger AG Karger |
| Publisher_xml | – name: S. Karger AG – name: Karger |
| References | Boyle DP, Zembower TR, Reddy S, et al: Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med 2015;191:1310-1317.2583509010.1164/rccm.201501-0067OC Henry MT, Inamdar L, O'Riordain D, et al: Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 2004;23:741-746.1517669010.1183/09031936.04.00114004 Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994;49:442-445.801676310.1136/thx.49.5.442 Carrillo MC, Patsios D, Wagnetz U, et al: Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi. Can Assoc Radiol J 2014;65:207-213.2432592410.1016/j.carj.2013.05.006 Research Committee of the British Thoracic Society: First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-172.1118200610.1136/thorax.56.3.167 Hoefsloot W, Boeree MJ, van Ingen J, et al: The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis 2008;12:987-993.18713494 Griffith DE, Aksamit T, Brown-Elliott BA, et al: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.1727729010.1164/rccm.200604-571ST Lehmann KB, Neumann R: Atlas und Grundriss der Bakteriologie und Lehrbuch der speziellen bakteriologischen Diagnostik, ed 1. München, J.F. Lehmann, 1896. Bicmen C, Gunduz AT, Coskun M, et al: Molecular detection and identification of Mycobacterium tuberculosis complex and four clinically important nontuberculous mycobacterial species in smear-negative clinical samples by the genotype mycobacteria direct test. J Clin Microbiol 2011;49:2874-2878.2165378010.1128/JCM.00612-11 Floto RA, Olivier KN, Saiman L, et al: US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016;71(suppl 1):i1-i22.2666625910.1136/thoraxjnl-2015-207360 Shafran SD, Singer J, Zarowny DP, et al: Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 1998;177:252-255.941920110.1086/517366 van Ingen J, Hoefsloot W, Dekhuijzen PN, et al: The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010;14:1176-1180.20819265 Marras TK, Wallace RJ Jr, Koth LL, et al: Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005;127:664-671.1570601310.1378/chest.127.2.664 Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al: In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 2013;51:3389-3394.2394652310.1128/JCM.01612-13 Harada T, Akiyama Y, Kurashima A, et al: Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012;50:3556-3561.2291561310.1128/JCM.01175-12 Van Deun A, Maug AK, Salim MA, et al: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.2044243210.1164/rccm.201001-0077OC Andrejak C, Thomsen VØ, Johansen IS, et al: Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010;181:514-521.2000792910.1164/rccm.200905-0778OC Yano Y, Kitada S, Mori M, et al: Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan. Respiration 2013;85:305-311.2289013010.1159/000339631 Tillie-Leblond I, Grenouillet F, Reboux G, et al: Hypersensitivity pneumonitis and metalworking fluids contaminated by mycobacteria. Eur Respir J 2011;37:640-647.2069325410.1183/09031936.00195009 van Ingen J: Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med 2015;36:43-54.2567651810.1016/j.ccm.2014.11.005 Roussel G, Igual J: Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections a Mycobacteries. Int J Tuberc Lung Dis 1998;2:462-470.9626603 Olivier KN, Shaw PA, Glaser TS, et al: Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014;11:30-35.2446043710.1513/AnnalsATS.201307-231OC Jo KW, Kim S, Lee JY, et al: Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother 2014;20:602-606.2498171410.1016/j.jiac.2014.05.010 European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. 2015. http://www.eucast.org. Santos M, Gil-Brusola A, Escandell A, et al: Mycobacterium genavense infections in a tertiary hospital and reviewed cases in non-HIV patients. Patholog Res Int 2014;2014:371370.2469345610.1155/2014/371370 Wallace RJ Jr, Zhang Y, Wilson RW, et al: Presence of a single genotype of the newly described species Mycobacterium immunogenum in industrial metalworking fluids associated with hypersensitivity pneumonitis. Appl Environ Microbiol 2002;68:5580-5584.1240675210.1128/AEM.68.11.5580-5584.2002 Brown-Elliott BA, Crist CJ, Mann LB, et al: In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 2003;47:1736-1738.1270934910.1128/AAC.47.5.1736-1738.2003 Maurer FP, Castelberg C, Quiblier C, et al: Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 2014;69:1559-1563.2450018810.1093/jac/dku007 Horsburgh CR Jr, Mason UG 3rd, Heifets LB, et al: Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 1987;135:418-421.3813205 Hoefsloot W, van Ingen J, Andrejak C, et al: The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013;42:1604-1613.2359895610.1183/09031936.00149212 Jankovic M, Samarzija M, Sabol I, et al: Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis 2013;17:836-841.2367617210.5588/ijtld.12.0843 Cayrou C, Turenne C, Behr MA, et al: Genotyping of Mycobacterium avium complex organisms using multispacer sequence typing. Microbiology 2010;156:687-694.1992665210.1099/mic.0.033522-0 Gommans EP, Even P, Linssen CF, et al: Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. Respir Med 2015;109:137-145.2546490510.1016/j.rmed.2014.10.013 McCallum AD, Watkin SW, Faccenda JF: Non-tuberculous mycobacterial infections in the Scottish Borders: identification, management and treatment outcomes - a retrospective review. J R Coll Physicians Edinb 2011;41:294-303.2218456610.4997/JRCPE.2011.403 Jeong BH, Jeon K, Park HY, et al: Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015;191:96-103.2539352010.1164/rccm.201408-1545OC Rickman OB, Ryu JH, Fidler ME, et al: Hypersensitivity pneumonitis associated with Mycobacterium avium complex and hot tub use. Mayo Clin Proc 2002;77:1233-1237.1244056010.4065/77.11.1233 Wang HY, Bang H, Kim S, et al: Identification of Mycobacterium species in direct respiratory specimens using reverse blot hybridisation assay. Int J Tuberc Lung Dis 2014;18:1114-1120.2518956210.5588/ijtld.14.0140 Pezzia W, Raleigh JW, Bailey MC, et al: Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981;3:1035-1039.733980110.1093/clinids/3.5.1035 Prevots DR, Shaw PA, Strickland D, et al: Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.2053895810.1164/rccm.201002-0310OC Andrejak C, Nielsen R, Thomsen VØ, et al: Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68:256-262.2278112310.1136/thoraxjnl-2012-201772 Hankwitz PE, Cervia JS, Thomas CF, et al: Nontuberculous mycobacterial hypersensitivity pneumonitis related to a home shower: treatment and secondary prevention. BMJ Case Rep 2011;2011:bcr0620114360.2268984710.1136/bcr.06.2011.4360 Aitken ML, Limaye A, Pottinger P, et al: Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012;185:231-232.2224671010.1164/ajrccm.185.2.231 Schönfeld N, Haas W, Richter E, et al: Recommendations for diagnosis and treatment of nontuberculous mycobacterioses of the German Central Committee against Tuberculosis and the German Respiratory Society (in German). Pneumologie 2013;67:605-633.2419823710.1055/s-0033-1344790 van Ingen J, Verhagen AF, Dekhuijzen PN, et al: Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis 2010;14:99-105.20003702 Richter E, Beer J, Diel R, Hillemann D, Hoffmann H, Klotz M, Mauch H, Rüsch-Gerdes S: MiQ 5: Tuberkulose Mykobakteriose, ed 2. Berlin, Elsevier, 20 ref57 ref56 ref59 ref58 ref53 ref52 ref55 ref54 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref100 ref101 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref39 ref38 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref13 ref12 ref15 ref128 ref14 ref129 ref97 ref126 ref96 ref127 ref11 ref99 ref124 ref10 ref98 ref125 ref17 ref16 ref19 ref18 ref93 ref92 ref95 ref94 ref130 ref91 ref90 ref89 ref86 ref85 ref88 ref87 ref82 ref81 ref84 ref83 ref80 ref79 ref108 ref78 ref109 ref106 ref107 ref75 ref104 ref74 ref105 ref77 ref102 ref76 ref103 ref2 ref1 ref71 ref111 ref70 ref112 ref73 ref72 ref110 ref68 ref119 ref67 ref117 ref69 ref118 ref64 ref115 ref63 ref116 ref66 ref113 ref65 ref114 ref60 ref122 ref123 ref62 ref120 ref61 ref121 |
| References_xml | – reference: Medical Microbiology - Diagnosis of Tuberculosis - Part 3: Detection of Mycobacteria by Culture Methods; text in German and English. Berlin, Beuth, 2011. – reference: Honda JR, Knight V, Chan ED: Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin Chest Med 2015;36:1-11.2567651510.1016/j.ccm.2014.10.001 – reference: Andrejak C, Almeida DV, Tyagi S, et al: Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother 2013;68:659-665.2312973010.1093/jac/dks421 – reference: Kobashi Y, Matsushima T, Oka M: A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007;101:130-138.1675061810.1016/j.rmed.2006.04.002 – reference: Moore JE, Kruijshaar ME, Ormerod LP, et al: Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health 2010;10:612.2095042110.1186/1471-2458-10-612 – reference: Koh WJ, Jeong BH, Jeon K, et al: Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;186:797-802.2287828210.1164/rccm.201206-1088OC – reference: Choi GE, Shin SJ, Won CJ, et al: Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012;186:917-925.2287828110.1164/rccm.201111-2005OC – reference: Boyle DP, Zembower TR, Reddy S, et al: Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med 2015;191:1310-1317.2583509010.1164/rccm.201501-0067OC – reference: Jarand J, Levin A, Zhang L, et al: Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52:565-571.2129265910.1093/cid/ciq237 – reference: Jo KW, Kim S, Lee JY, et al: Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother 2014;20:602-606.2498171410.1016/j.jiac.2014.05.010 – reference: Floto RA, Olivier KN, Saiman L, et al: US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax 2016;71:88-90.2667843510.1136/thoraxjnl-2015-207983 – reference: Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, et al: Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011;24:701-717.2197660510.1128/CMR.00020-11 – reference: Heifets L, Mor N, Vanderkolk J: Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993;37:2364-2370.803135110.1128/AAC.37.11.2364 – reference: Yano Y, Kitada S, Mori M, et al: Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan. Respiration 2013;85:305-311.2289013010.1159/000339631 – reference: van Ingen J, Boeree MJ, de Lange WC, et al: Mycobacterium xenopi clinical relevance and determinants, the Netherlands. Emerg Infect Dis 2008;14:385-389.1832525110.3201/eid1403.061393 – reference: Ingen JV, Kuijper EJ: Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol 2014;9:1095-1110.2534083810.2217/fmb.14.60 – reference: Huang JH, Kao PN: Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease diagnostic and management limitations. Chest 1999;115:1033-1040.1020820510.1378/chest.115.4.1033 – reference: Shafran SD, Singer J, Zarowny DP, et al: Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for Mycobacterium avium complex bacteremia: a multivariate analysis. Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis 1998;177:252-255.941920110.1086/517366 – reference: van Ingen J, Griffith DE, Aksamit TA, et al: Pulmonary diseases caused by non-tuberculous mycobacteria. Eur Respir Monogr 2012;58:25-37. – reference: Adékambi T, Berger P, Raoult D, et al: rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006;56:133-143.1640387810.1099/ijs.0.63969-0 – reference: van Ingen J, Bendien SA, de Lange WC, et al: Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64:502-506.1921377310.1136/thx.2008.110957 – reference: Heyckendorf J, Olaru ID, Ruhwald M, et al: Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2014;190:374-383.2494130610.1164/rccm.201402-0363PP – reference: Thomsen VØ, Andersen AB, Miörner H: Incidence and clinical significance of non-tuberculous mycobacteria isolated from clinical specimens during a 2-y nationwide survey. Scand J Infect Dis 2002;34:648-653.1237435310.1080/00365540210147813 – reference: Brent AJ, Mugo D, Musyimi R, et al: Performance of the MGIT TBc identification test and meta-analysis of MPT64 assays for identification of the Mycobacterium tuberculosis complex in liquid culture. J Clin Microbiol 2011;49:4343-4346.2199842610.1128/JCM.05995-11 – reference: Moon SM, Park HY, Jeon K, et al: Clinical significance of Mycobacterium kansasii isolates from respiratory specimens. PLoS One 2015;10:e0139621.2643154010.1371/journal.pone.0139621 – reference: Wang HY, Bang H, Kim S, et al: Identification of Mycobacterium species in direct respiratory specimens using reverse blot hybridisation assay. Int J Tuberc Lung Dis 2014;18:1114-1120.2518956210.5588/ijtld.14.0140 – reference: Richter E, Beer J, Diel R, Hillemann D, Hoffmann H, Klotz M, Mauch H, Rüsch-Gerdes S: MiQ 5: Tuberkulose Mykobakteriose, ed 2. Berlin, Elsevier, 2010. – reference: Brown-Elliott BA, Crist CJ, Mann LB, et al: In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 2003;47:1736-1738.1270934910.1128/AAC.47.5.1736-1738.2003 – reference: Floto RA, Olivier KN, Saiman L, et al: US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016;71(suppl 1):i1-i22.2666625910.1136/thoraxjnl-2015-207360 – reference: Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000;55:210-218.1067954010.1136/thorax.55.3.210 – reference: Wallace RJ Jr, Brown BA, Griffith DE, et al: Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med 1996;153:1766-1772.866503210.1164/ajrccm.153.6.8665032 – reference: Egelund EF, Fennelly KP, Peloquin CA: Medications and monitoring in nontuberculous mycobacteria infections. Clin Chest Med 2015;36:55-66.2567651910.1016/j.ccm.2014.11.001 – reference: Greco S, Rulli M, Girardi E, et al: Diagnostic accuracy of in-house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and metaregression. J Clin Microbiol 2009;47:569-576.1914479710.1128/JCM.02051-08 – reference: Nessar R, Cambau E, Reyrat JM, et al: Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67:810-818.2229034610.1093/jac/dkr578 – reference: Shen GH, Wu BD, Hu ST, et al: High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010;35:400-404.2013848110.1016/j.ijantimicag.2009.12.008 – reference: Park YS, Lee CH, Lee SM, et al: Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis 2010;14:1069-1071.20626955 – reference: Carrillo MC, Patsios D, Wagnetz U, et al: Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi. Can Assoc Radiol J 2014;65:207-213.2432592410.1016/j.carj.2013.05.006 – reference: van Ingen J, Hoefsloot W, Dekhuijzen PN, et al: The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010;14:1176-1180.20819265 – reference: Ferro BE, van Ingen J, Wattenberg M, et al: Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. J Antimicrob Chemother 2015;70:2838-2843.2614247510.1093/jac/dkv180 – reference: Prevots DR, Marras TK: Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015;36:13-34.2567651610.1016/j.ccm.2014.10.002 – reference: Falkinham JO 3rd: Environmental sources of nontuberculous mycobacteria. Clin Chest Med 2015;36:35-41.2567651710.1016/j.ccm.2014.10.003 – reference: Russell CD, Claxton P, Doig C, et al: Non- tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax 2014;69:593-595.2398639110.1136/thoraxjnl-2013-204260 – reference: Kang HK, Park HY, Kim D, et al: Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis 2015;15:76.2588719110.1186/s12879-015-0823-1 – reference: Greco S, Girardi E, Navarra A, et al: Current evidence on diagnostic accuracy of commercially based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 2006;61:783-790.16738037 10.1136/thx.2005.054908 – reference: Bryant JM, Grogono DM, Greaves D, et al: Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013;381:1551-1560.2354154010.1016/S0140-6736(13)60632-7 – reference: Hoefsloot W, van Ingen J, Andrejak C, et al: The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013;42:1604-1613.2359895610.1183/09031936.00149212 – reference: Sorlozano A, Soria I, Roman J, et al: Comparative evaluation of three culture methods for the isolation of mycobacteria from clinical samples. J Microbiol Biotechnol 2009;19:1259-1264.19884789 – reference: Henry MT, Inamdar L, O'Riordain D, et al: Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J 2004;23:741-746.1517669010.1183/09031936.04.00114004 – reference: Cayrou C, Turenne C, Behr MA, et al: Genotyping of Mycobacterium avium complex organisms using multispacer sequence typing. Microbiology 2010;156:687-694.1992665210.1099/mic.0.033522-0 – reference: Hanak V, Kalra S, Aksamit TR, et al: Hot tub lung: presenting features and clinical course of 21 patients. Respir Med 2006;100:610-615.1619460110.1016/j.rmed.2005.08.005 – reference: Olivier KN, Shaw PA, Glaser TS, et al: Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014;11:30-35.2446043710.1513/AnnalsATS.201307-231OC – reference: Davies BS, Roberts CH, Kaul S, et al: Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. Scand J Infect Dis 2012;44:815-819.2307852910.3109/00365548.2012.694469 – reference: Panagiotou M, Papaioannou AI, Kostikas K, et al: The epidemiology of pulmonary nontuberculous mycobacteria: data from a general hospital in Athens, Greece, 2007-2013. Pulm Med 2014;2014:894976.2513299110.1155/2014/894976 – reference: Hankwitz PE, Cervia JS, Thomas CF, et al: Nontuberculous mycobacterial hypersensitivity pneumonitis related to a home shower: treatment and secondary prevention. BMJ Case Rep 2011;2011:bcr0620114360.2268984710.1136/bcr.06.2011.4360 – reference: Cappelluti E, Fraire AE, Schaefer OP: A case of ‘hot tub lung' due to Mycobacterium avium complex in an immunocompetent host. Arch Intern Med 2003;163:845-848.1269527610.1001/archinte.163.7.845 – reference: Santos M, Gil-Brusola A, Escandell A, et al: Mycobacterium genavense infections in a tertiary hospital and reviewed cases in non-HIV patients. Patholog Res Int 2014;2014:371370.2469345610.1155/2014/371370 – reference: Jeon K, Kwon OJ, Lee NY, et al: Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.1966124310.1164/rccm.200905-0704OC – reference: Maurer FP, Castelberg C, Quiblier C, et al: Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 2014;69:1559-1563.2450018810.1093/jac/dku007 – reference: Schönfeld N, Haas W, Richter E, et al: Recommendations for diagnosis and treatment of nontuberculous mycobacterioses of the German Central Committee against Tuberculosis and the German Respiratory Society (in German). Pneumologie 2013;67:605-633.2419823710.1055/s-0033-1344790 – reference: Jenkins PA, Campbell IA, Banks J, et al: Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008;63:627-634.1825018410.1136/thx.2007.087999 – reference: Johnson MM, Odell JA: Nontuberculous mycobacterial pulmonary infections. J Thorac Dis 2014;6:210-220.2462428510.3978/j.issn.2072-1439.2013.12.24 – reference: Lahiri A, Kneisel J, Kloster I, et al: Abundance of Mycobacterium avium ssp. hominissuis in soil and dust in Germany - implications for the infection route. Lett Appl Microbiol 2014;59:65-70.2461201610.1111/lam.12243 – reference: Ricketts WM, O'Shaughnessy TC, van Ingen J: Human-to-human transmission of Mycobacterium kansasii or victims of a shared source? Eur Respir J 2014;44:1085-1087.2496965210.1183/09031936.00066614 – reference: Maugein J, Dailloux M, Carbonnelle B, et al: Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease. Eur Respir J 2005;26:1092-1096.1631934110.1183/09031936.05.00148604 – reference: Wassilew N, Lange C: Cure not possible, by definition. Am J Respir Crit Care Med 2015;192:1255-1256.2656824310.1164/rccm.201507-1392LE – reference: Gommans EP, Even P, Linssen CF, et al: Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. Respir Med 2015;109:137-145.2546490510.1016/j.rmed.2014.10.013 – reference: Buchan BW, Riebe KM, Timke M, et al: Comparison of MALDI-TOF MS with HPLC and nucleic acid sequencing for the identification of Mycobacterium species in cultures using solid medium and broth. Am J Clin Pathol 2014;141:25-34.2434373410.1309/AJCPBPUBUDEW2OAG – reference: Roussel G, Igual J: Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections a Mycobacteries. Int J Tuberc Lung Dis 1998;2:462-470.9626603 – reference: Griffith DE, Philley JV, Brown-Elliott BA, et al: The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. Chest 2015;147:1369-1375.2535707410.1378/chest.14-1297 – reference: Dunne M, Fessel J, Kumar P, et al: A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000;31:1245-1252.1107375910.1086/317468 – reference: Apseloff G, Foulds G, LaBoy-Goral L, et al: Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol 1998;38:830-835.9753212 – reference: Marchetti N, Criner K, Criner GJ: Characterization of functional, radiologic and lung function recovery post-treatment of hot tub lung. A case report and review of the literature. Lung 2004;182:271-277.1574223910.1007/s00408-004-2508-1 – reference: Tillie-Leblond I, Grenouillet F, Reboux G, et al: Hypersensitivity pneumonitis and metalworking fluids contaminated by mycobacteria. Eur Respir J 2011;37:640-647.2069325410.1183/09031936.00195009 – reference: Pezzia W, Raleigh JW, Bailey MC, et al: Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981;3:1035-1039.733980110.1093/clinids/3.5.1035 – reference: European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. 2015. http://www.eucast.org. – reference: Cassidy PM, Hedberg K, Saulson A, et al: Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009;49:e124-e129.1991194210.1086/648443 – reference: Hollings NP, Wells AU, Wilson R, et al: Comparative appearances of non-tuberculous mycobacteria species: a CT study. Eur Radiol 2002;12:2211-2217.1219547210.1007/s00330-001-1282-1 – reference: Bicmen C, Gunduz AT, Coskun M, et al: Molecular detection and identification of Mycobacterium tuberculosis complex and four clinically important nontuberculous mycobacterial species in smear-negative clinical samples by the genotype mycobacteria direct test. J Clin Microbiol 2011;49:2874-2878.2165378010.1128/JCM.00612-11 – reference: Jankovic M, Samarzija M, Sabol I, et al: Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis 2013;17:836-841.2367617210.5588/ijtld.12.0843 – reference: Ripoll F, Pasek S, Schenowitz C, et al: Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009;4:e5660.1954352710.1371/journal.pone.0005660 – reference: van Ingen J, Ferro BE, Hoefsloot W, et al: Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev Anti Infect Ther 2013;11:1065-1077.2412479810.1586/14787210.2013.830413 – reference: Dailloux M, Abalain ML, Laurain C, et al: Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J 2006;28:1211-1215.1713867810.1183/09031936.00063806 – reference: Griffith DE, Aksamit T, Brown-Elliott BA, et al: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.1727729010.1164/rccm.200604-571ST – reference: van Ingen J, Lindeboom JA, Hartwig NG, et al: Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species. Int J Syst Evol Microbiol 2009;59:2782-2787.1962542510.1099/ijs.0.010405-0 – reference: Koh WJ, Kwon OJ, Jeon K, et al: Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006;129:341-348.1647885010.1378/chest.129.2.341 – reference: Koh W-J, Jeon K, Lee NY, et al: Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.2083382310.1164/rccm.201003-0395OC – reference: Kim BJ, Math RK, Jeon CO, et al: Mycobacterium yongonense sp. nov., a slow-growing non-chromogenic species closely related to Mycobacterium intracellulare. Int J Syst Evol Microbiol 2013;63:192-199.2242744210.1099/ijs.0.037465-0 – reference: Ahn CH, Lowell JR, Ahn SS, et al: Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983;128:1048-1050.6650978 – reference: van Ingen J, Verhagen AF, Dekhuijzen PN, et al: Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. Int J Tuberc Lung Dis 2010;14:99-105.20003702 – reference: Prevots DR, Shaw PA, Strickland D, et al: Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.2053895810.1164/rccm.201002-0310OC – reference: Schluger NW: Treatment of pulmonary Mycobacterium avium complex infections: do drug levels matter? Am J Respir Crit Care Med 2012;186:710-711.2307118810.1164/rccm.201208-1478ED – reference: McShane PJ, Glassroth J: Pulmonary disease due to nontuberculous mycobacteria: current state and new insights. Chest 2015;148:1517-1527.2622580510.1378/chest.15-0458 – reference: Wright PW, Wallace RJ Jr, Wright NW, et al: Sensitivity of fluorochrome microscopy for detection of Mycobacterium tuberculosis versus nontuberculous mycobacteria. J Clin Microbiol 1998;36:1046-1049.9542935 – reference: Piersimoni C, Nista D, Bornigia S, et al: Unreliable detection of Mycobacterium xenopi by the nonradiometric Bactec MGIT 960 culture system. J Clin Microbiol 2009;47:804-806.1914480210.1128/JCM.01444-08 – reference: Hoefsloot W, van Ingen J, de Lange WC, et al: Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J 2009;34:926-931.1938668910.1183/09031936.00039009 – reference: Lehmann KB, Neumann R: Atlas und Grundriss der Bakteriologie und Lehrbuch der speziellen bakteriologischen Diagnostik, ed 1. München, J.F. Lehmann, 1896. – reference: Martín-Casabona N, Bahrmand AR, Bennedsen J, et al: Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004;8:1186-1193.15527150 – reference: Falkinham JO 3rd: Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009;107:356-367.1922825810.1111/j.1365-2672.2009.04161.x – reference: Plotinsky RN, Talbot EA, von Reyn CF: Proposed definitions for epidemiologic and clinical studies of Mycobacterium avium complex pulmonary disease. PLoS One 2013;8: e77385.2426567510.1371/journal.pone.0077385 – reference: Miwa S, Shirai M, Toyoshima M, et al: Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc 2014;11:23-29.2429890710.1513/AnnalsATS.201308-266OC – reference: LPSN: List of prokaryotic names with standing in nomenclature: genus Mycobacterium. 2014. www.bacterio.net. – reference: Lee BY, Kim S, Hong Y, et al: Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob Agents Chemother 2015;59:2972-2977.2575363410.1128/AAC.04577-14 – reference: Brode SK, Daley CL, Marras TK: The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuberc Lung Dis 2014;18:1370-1377.2529987310.5588/ijtld.14.0120 – reference: Ellis SM, Hansell DM: Imaging of non-tuberculous (atypical) mycobacterial pulmonary infection. Clin Radiol 2002;57:661-669.1216927710.1053/crad.2001.0851 – reference: Wallace RJ Jr, Zhang Y, Wilson RW, et al: Presence of a single genotype of the newly described species Mycobacterium immunogenum in industrial metalworking fluids associated with hypersensitivity pneumonitis. Appl Environ Microbiol 2002;68:5580-5584.1240675210.1128/AEM.68.11.5580-5584.2002 – reference: Rose SJ, Neville ME, Gupta R, et al: Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One 2014;9:e108703.2526475710.1371/journal.pone.0108703 – reference: Bastian S, Veziris N, Roux AL, et al: Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011;55:775-781.2113518510.1128/AAC.00861-10 – reference: Kasperbauer SH, De Groote MA: The treatment of rapidly growing mycobacterial infections. Clin Chest Med 2015;36:67-78.2567652010.1016/j.ccm.2014.10.004 – reference: Valero G, Moreno F, Graybill JR: Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. Antimicrob Agents Chemother 1994;38:2676-2677.787276910.1128/AAC.38.11.2676 – reference: van Ingen J: Microbiological diagnosis of nontuberculous mycobacterial pulmonary disease. Clin Chest Med 2015;36:43-54.2567651810.1016/j.ccm.2014.11.005 – reference: Magis-Escurra C, Alffenaar JW, Hoefnagels I, et al: Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. Int J Antimicrob Agents 2013;42:256-261.2383792310.1016/j.ijantimicag.2013.05.007 – reference: Harada T, Akiyama Y, Kurashima A, et al: Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 2012;50:3556-3561.2291561310.1128/JCM.01175-12 – reference: Andrejak C, Thomsen VØ, Johansen IS, et al: Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010;181:514-521.2000792910.1164/rccm.200905-0778OC – reference: Winthrop KL, Ku JH, Marras TK, et al: The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J 2015;45:1177-1179.2561416910.1183/09031936.00169114 – reference: Kasai H, Ezaki T, Harayama S: Differentiation of phylogenetically related slowly growing mycobacteria by their gyrB sequences. J Clin Microbiol 2000;38:301-308.10618105 – reference: Ringshausen FC, Apel RM, Bange FC, et al: Burden and trends of hospitalisations associated with pulmonary non-tuberculous mycobacterial infections in Germany, 2005-2011. BMC Infect Dis 2013;13:231.2369286710.1186/1471-2334-13-231 – reference: Adams LL, Salee P, Dionne K, et al: A novel protein extraction method for identification of mycobacteria using MALDI-ToF MS. J Microbiol Methods 2015;119:1-3.2639229310.1016/j.mimet.2015.09.010 – reference: Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al: Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest 2014;146:276-282.2445754210.1378/chest.13-2538 – reference: Brown-Elliott BA, Iakhiaeva E, Griffith DE, et al: In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 2013;51:3389-3394.2394652310.1128/JCM.01612-13 – reference: Jeong BH, Jeon K, Park HY, et al: Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015;191:96-103.2539352010.1164/rccm.201408-1545OC – reference: Marras TK, Wallace RJ Jr, Koth LL, et al: Hypersensitivity pneumonitis reaction to Mycobacterium avium in household water. Chest 2005;127:664-671.1570601310.1378/chest.127.2.664 – reference: Wolinsky E: When is an infection disease? Rev Infect Dis 1981;3:1025-1027.7339799 – reference: Ide S, Nakamura S, Yamamoto Y, et al: Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One 2015;10:e0128304.2602094810.1371/journal.pone.0128304 – reference: van Ingen J, Boeree MJ, Kosters K, et al: Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst Evol Microbiol 2009;59:2277-2282.1962037610.1099/ijs.0.008854-0 – reference: Van Deun A, Maug AK, Salim MA, et al: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.2044243210.1164/rccm.201001-0077OC – reference: Aitken ML, Limaye A, Pottinger P, et al: Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 2012;185:231-232.2224671010.1164/ajrccm.185.2.231 – reference: Field SK, Cowie RL: Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003;124:1482-1486.1455558310.1378/chest.124.4.1482 – reference: Klemens SP, Cynamon MH: Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother 1994;38:1455-1459.797927110.1128/AAC.38.7.1455 – reference: Hoefsloot W, Boeree MJ, van Ingen J, et al: The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis 2008;12:987-993.18713494 – reference: van der Werf MJ, Ködmön C, Katalinić-Janković V, et al: Inventory study of non- tuberculous mycobacteria in the European Union. BMC Infect Dis 2014;14:62.2450246210.1186/1471-2334-14-62 – reference: Chou MP, Clements ACA, Thomson RM: A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis 2014;14:279.2488591610.1186/1471-2334-14-279 – reference: Koh WJ, Jeon K, Lee NY, et al: Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.2083382310.1164/rccm.201003-0395OC – reference: Horsburgh CR Jr, Mason UG 3rd, Heifets LB, et al: Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 1987;135:418-421.3813205 – reference: van Ingen J, Totten SE, Helstrom NK, et al: In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012;56:6324-6327.2302718910.1128/AAC.01505-12 – reference: Leao SC, Tortoli E, Euzéby JP, et al: Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011;61:2311-2313.2103703510.1099/ijs.0.023770-0 – reference: Benwill JL, Wallace RJ Jr: Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis 2014;27:506-510.2526892510.1097/QCO.0000000000000104 – reference: Andrejak C, Nielsen R, Thomsen VØ, et al: Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013;68:256-262.2278112310.1136/thoraxjnl-2012-201772 – reference: Rickman OB, Ryu JH, Fidler ME, et al: Hypersensitivity pneumonitis associated with Mycobacterium avium complex and hot tub use. Mayo Clin Proc 2002;77:1233-1237.1244056010.4065/77.11.1233 – reference: Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. Thorax 1994;49:442-445.801676310.1136/thx.49.5.442 – reference: Research Committee of the British Thoracic Society: First randomised trial of treatments for pulmonary disease caused by M. avium intracellulare, M. malmoense, and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001;56:167-172.1118200610.1136/thorax.56.3.167 – reference: Embil J, Warren P, Yakrus M: Pulmonary illness associated with exposure to Mycobacterium avium complex in hot tub water hypersensitivity pneumonitis or infection? Chest 1997;111:813-816.371821610.1001/archsurg.1986.01400070079017 – reference: M24-A2: Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard, ed 2, vol 31, No 5. Wayne, National Committee for Clinical Laboratory Standards, 2011. – reference: van Ingen J: Treatment of pulmonary disease caused by non-tuberculous mycobacteria. Lancet Respir Med 2015;3:179-180.2577320810.1016/S2213-2600(15)00033-8 – reference: Marras TK, Chedore P, Ying AM, et al: Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007;62:661-666.1731184210.1136/thx.2006.070797 – reference: van Ingen J, Boeree MJ, van Soolingen D, et al: Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012;15:149-161.2252552410.1016/j.drup.2012.04.001 – reference: McCallum AD, Watkin SW, Faccenda JF: Non-tuberculous mycobacterial infections in the Scottish Borders: identification, management and treatment outcomes - a retrospective review. J R Coll Physicians Edinb 2011;41:294-303.2218456610.4997/JRCPE.2011.403 – reference: van Ingen J, Egelund EF, Levin A, et al: The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186:559-565.2274471910.1164/rccm.201204-0682OC – reference: Philley JV, Wallace RJ Jr, Benwill JL, et al: Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 2015;148:499-506.2567539310.1378/chest.14-2764 – reference: Marras TK, Mendelson D, Marchand-Austin A, et al: Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013;19:1889-1891.2421001210.3201/eid1911.130737 – ident: ref27 doi: 10.1016/j.ccm.2014.10.002 – ident: ref77 doi: 10.1128/JCM.05995-11 – ident: ref56 doi: 10.1183/09031936.00039009 – ident: ref70 doi: 10.1136/thx.2005.054908 – ident: ref81 doi: 10.1016/j.drup.2012.04.001 – ident: ref21 doi: 10.1099/ijs.0.63969-0 – ident: ref61 doi: 10.1136/bcr.06.2011.4360 – ident: ref16 doi: 10.1099/ijs.0.010405-0 – ident: ref60 doi: 10.1378/chest.127.2.664 – ident: ref102 doi: 10.1378/chest.124.4.1482 – ident: ref39 doi: 10.1186/1471-2458-10-612 – ident: ref40 doi: 10.1136/thx.2008.110957 – ident: ref57 doi: 10.1007/s00330-001-1282-1 – ident: ref14 doi: 10.1136/thoraxjnl-2015-207360 – ident: ref31 doi: 10.1086/648443 – ident: ref129 doi: 10.1164/rccm.201402-0363PP – ident: ref5 doi: 10.1164/ajrccm.185.2.231 – ident: ref67 doi: 10.1001/archinte.163.7.845 – ident: ref58 doi: 10.3201/eid1403.061393 – ident: ref104 doi: 10.1513/AnnalsATS.201307-231OC – ident: ref35 doi: 10.1136/thoraxjnl-2013-204260 – ident: ref103 doi: 10.1093/jac/dkv180 – ident: ref127 doi: 10.1164/rccm.201111-2005OC – ident: ref13 doi: 10.1136/thoraxjnl-2015-207983 – ident: ref17 doi: 10.1099/ijs.0.008854-0 – ident: ref92 doi: 10.1128/JCM.01612-13 – ident: ref50 doi: 10.1183/09031936.05.00148604 – ident: ref112 doi: 10.1136/thx.2007.087999 – ident: ref63 doi: 10.1128/AEM.68.11.5580-5584.2002 – ident: ref49 doi: 10.1371/journal.pone.0128304 – ident: ref113 doi: 10.1136/thorax.56.3.167 – ident: ref42 doi: 10.1136/thoraxjnl-2012-201772 – ident: ref6 doi: 10.1016/S0140-6736(13)60632-7 – ident: ref86 doi: 10.1093/jac/dks421 – ident: ref37 doi: 10.1378/chest.15-0458 – ident: ref64 doi: 10.1016/j.rmed.2005.08.005 – ident: ref128 doi: 10.1093/jac/dku007 – ident: ref10 doi: 10.1136/thx.2006.070797 – ident: ref114 doi: 10.1128/AAC.38.11.2676 – ident: ref45 doi: 10.1378/chest.115.4.1033 – ident: ref78 doi: 10.1309/AJCPBPUBUDEW2OAG – ident: ref73 doi: 10.5588/ijtld.14.0140 – ident: ref19 doi: 10.1186/1471-2334-14-62 – ident: ref55 doi: 10.1159/000339631 – ident: ref91 doi: 10.1164/ajrccm.153.6.8665032 – ident: ref125 doi: 10.1016/j.ijantimicag.2009.12.008 – ident: ref116 doi: 10.1016/j.ccm.2014.10.004 – ident: ref119 doi: 10.2217/fmb.14.60 – ident: ref41 doi: 10.1155/2014/894976 – ident: ref96 doi: 10.1164/rccm.201206-1088OC – ident: ref32 doi: 10.1378/chest.129.2.341 – ident: ref30 doi: 10.1164/rccm.201002-0310OC – ident: ref23 doi: 10.1164/rccm.201003-0395OC – ident: ref68 doi: 10.1136/thorax.55.3.210 – ident: ref12 doi: 10.3201/eid1911.130737 – ident: ref4 doi: 10.1183/09031936.00066614 – ident: ref15 doi: 10.1099/mic.0.033522-0 – ident: ref38 doi: 10.1186/1471-2334-14-279 – ident: ref62 doi: 10.1183/09031936.00195009 – ident: ref18 doi: 10.1099/ijs.0.037465-0 – ident: ref9 doi: 10.1186/1471-2334-13-231 – ident: ref109 doi: 10.1183/09031936.00169114 – ident: ref97 doi: 10.1164/rccm.201208-1478ED – ident: ref106 doi: 10.1128/AAC.01505-12 – ident: ref120 doi: 10.1093/cid/ciq237 – ident: ref26 doi: 10.3978/j.issn.2072-1439.2013.12.24 – ident: ref75 doi: 10.1128/CMR.00020-11 – ident: ref100 doi: 10.1378/chest.13-2538 – ident: ref121 doi: 10.1164/rccm.200905-0704OC – ident: ref7 doi: 10.1183/09031936.04.00114004 – ident: ref11 doi: 10.5588/ijtld.14.0120 – ident: ref51 doi: 10.1183/09031936.00063806 – ident: ref117 doi: 10.1093/jac/dkr578 – ident: ref52 doi: 10.1378/chest.14-1297 – ident: ref80 doi: 10.1128/AAC.00861-10 – ident: ref36 doi: 10.1080/00365540210147813 – ident: ref8 doi: 10.4997/JRCPE.2011.403 – ident: ref83 doi: 10.1371/journal.pone.0077385 – ident: ref99 doi: 10.1164/rccm.201408-1545OC – ident: ref71 doi: 10.1128/JCM.02051-08 – ident: ref54 doi: 10.1371/journal.pone.0139621 – ident: ref93 doi: 10.1086/317468 – ident: ref108 doi: 10.1016/j.jiac.2014.05.010 – ident: ref82 doi: 10.1055/s-0033-1344790 – ident: ref53 doi: 10.1053/crad.2001.0851 – ident: ref122 doi: 10.1164/rccm.201003-0395OC – ident: ref24 doi: 10.1097/QCO.0000000000000104 – ident: ref3 doi: 10.1164/rccm.200604-571ST – ident: ref124 doi: 10.1016/S2213-2600(15)00033-8 – ident: ref130 doi: 10.1164/rccm.201001-0077OC – ident: ref44 doi: 10.1016/j.rmed.2014.10.013 – ident: ref20 doi: 10.1164/rccm.201501-0067OC – ident: ref87 doi: 10.1513/AnnalsATS.201308-266OC – ident: ref88 doi: 10.1016/j.rmed.2006.04.002 – ident: ref95 doi: 10.1164/rccm.201204-0682OC – ident: ref110 doi: 10.1093/clinids/3.5.1035 – ident: ref25 doi: 10.1183/09031936.00149212 – ident: ref47 doi: 10.1186/s12879-015-0823-1 – ident: ref69 doi: 10.1016/j.ccm.2014.11.005 – ident: ref89 doi: 10.1164/rccm.201507-1392LE – ident: ref74 doi: 10.1128/JCM.01444-08 – ident: ref33 doi: 10.1164/rccm.200905-0778OC – ident: ref2 doi: 10.1016/j.ccm.2014.10.003 – ident: ref101 doi: 10.1586/14787210.2013.830413 – ident: ref22 doi: 10.1099/ijs.0.023770-0 – ident: ref118 doi: 10.1371/journal.pone.0005660 – ident: ref1 doi: 10.1111/j.1365-2672.2009.04161.x – ident: ref34 doi: 10.5588/ijtld.12.0843 – ident: ref85 doi: 10.1128/AAC.38.7.1455 – ident: ref111 doi: 10.1136/thx.49.5.442 – ident: ref66 doi: 10.4065/77.11.1233 – ident: ref79 doi: 10.1016/j.mimet.2015.09.010 – ident: ref90 doi: 10.1128/AAC.37.11.2364 – ident: ref107 doi: 10.1128/AAC.47.5.1736-1738.2003 – ident: ref123 doi: 10.1128/JCM.01175-12 – ident: ref84 doi: 10.1016/j.ccm.2014.11.001 – ident: ref59 doi: 10.1001/archsurg.1986.01400070079017 – ident: ref43 doi: 10.1016/j.ccm.2014.10.001 – ident: ref105 doi: 10.1371/journal.pone.0108703 – ident: ref115 doi: 10.1128/AAC.01505-12 – ident: ref126 doi: 10.1378/chest.14-2764 – ident: ref28 doi: 10.1111/lam.12243 – ident: ref72 doi: 10.1128/JCM.00612-11 – ident: ref48 doi: 10.1016/j.carj.2013.05.006 – ident: ref46 doi: 10.1128/AAC.04577-14 – ident: ref29 doi: 10.3109/00365548.2012.694469 – ident: ref98 doi: 10.1086/517366 – ident: ref94 doi: 10.1016/j.ijantimicag.2013.05.007 – ident: ref65 doi: 10.1007/s00408-004-2508-1 – ident: ref76 doi: 10.1155/2014/371370 |
| SSID | ssj0015882 |
| Score | 2.478728 |
| SecondaryResourceType | review_article |
| Snippet | Non-tuberculous mycobacteria (NTM) include more than 160 ubiquitous, environmental, acid-fast-staining bacterial species, some of which may cause disease in... |
| SourceID | swepub hal proquest gale pubmed crossref karger |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 386 |
| SubjectTerms | Causes of Complications and side effects Cystic fibrosis Demographics Epidemiology Europe - epidemiology HIV Human immunodeficiency virus Humans Immune system Infections Life Sciences Lung - diagnostic imaging Lung diseases Mycobacterium avium Complex Mycobacterium avium-intracellulare Infection - diagnosis Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - epidemiology Mycobacterium infections Mycobacterium Infections, Nontuberculous - diagnosis Mycobacterium Infections, Nontuberculous - drug therapy Mycobacterium Infections, Nontuberculous - epidemiology Mycobacterium Infections, Nontuberculous - microbiology Mycobacterium kansasii Mycobacterium xenopi Nontuberculous Mycobacteria Pathogens Population Review Risk factors Tomography, X-Ray Computed Tuberculosis Tuberculosis, Pulmonary - diagnosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - epidemiology Tuberculosis, Pulmonary - microbiology |
| Title | Pulmonary Disease Caused by Non-Tuberculous Mycobacteria |
| URI | https://karger.com/doi/10.1159/000445906 https://www.ncbi.nlm.nih.gov/pubmed/27207809 https://www.proquest.com/docview/3043187241 https://www.proquest.com/docview/1797872318 https://u-picardie.hal.science/hal-03591346 http://kipublications.ki.se/Default.aspx?queryparsed=id:133767203 |
| Volume | 91 |
| WOSCitedRecordID | wos000377991300006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Career & Technical Education Database customDbUrl: eissn: 1423-0356 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0015882 issn: 0025-7931 databaseCode: 7RQ dateStart: 19980101 isFulltext: true titleUrlDefault: https://search.proquest.com/career providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1423-0356 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0015882 issn: 0025-7931 databaseCode: 7X7 dateStart: 19980101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1423-0356 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0015882 issn: 0025-7931 databaseCode: BENPR dateStart: 19980101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1423-0356 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0015882 issn: 0025-7931 databaseCode: M2O dateStart: 19980101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYhxAvfA4IjBIQQrxEJHH89VjGpj3QUqYh9c2yHUegVSlqm0n977lLXIuhIfFiRY7jnHx3vrPP_h0h72xZC9MUKqOe5VlVeFApVxdZk1NmuGls5WWfbEJMp3I-V7Ow34F3Ya7w_HMPjRqxBcDgfuwDj0whtvYBGNxeBSdZFuMFTMoyJmdVtAgYQjc-RdxfUYJJxMOHfxihMBXv_cCTkIcDAbf5m3-BifYG6OzB_5P-kNwPTmY6HqTiEbnj28fk7iSE0Z8QOesWIH5mtU0_DwGa9MR0a1-ndptOl2122Vm_ct1i2a3TydaBzveYzuaIfD87vTw5z0IKhczBTLbJais4s7zgBrOL1VRZpnxuMBYH1cYJCw6QKblyvmYctF1wPPfEvcy9lFbRp2S_Xbb-OUmprGq89OFo4SsFnCwds03JLJNNU3uTkA-7MdUu4ItjmouF7tcZTOk4Egl5G5v-GkA1bmv0Ghmjh_ugURH1mFNYgjIuJXQDPIs9IFD2-fiLxjoEJixoxa-LhBwNjIntdt0f7zisg9quNUWoISnAq0nIm_gaFA6jKKb1MOoaZjCY5MAthv8_GyQjdr2Tr4S8H0TlBnGh6gqevAbPM6_4i39Q95LcA88s7PUck_3NqvOvyKG73vxcr0ZkT1x8w3Iu-lKOyMGn0-nsYtRrBZbl19-t1vwy |
| linkProvider | Karger AG |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgTMALnwPCBgsIIV6sJXHs2I_VYCqirfZQpL1ZtuOIaVWK2mZS_3vuEtdi05B4ixznYvnufGff-XeEfLJFXZkmV5R5ntEy96BSrs5pkzFuhGls6WVfbKKazeTFhToP5x14F-YK8597aNSILQAG96QPPHKF2NoPKsULTN6bUhrjBVzKIhZnVSwPGEI3PkXc36oAk4jJh38ZobAU3_-FmZD7wwDu8jdvgYn2Bujs6f8P_Rl5EpzMdDRIxXNyz7cvyMNpCKO_JPK8W4D4mdU2_ToEaNJT0619ndptOlu2dN5Zv3LdYtmt0-nWgc73mM7mgPw8-zY_HdNQQoE6WMk2tLaV4FbkwmB1sZopy5XPDMbioNm4yoIDZAqhnK-5AG2vBOY9CS8zL6VV7BXZa5etf0NSJssaL304lvtSAScLx21TcMtl09TeJOTLbk61C_jiWOZioft9Blc6zkRCPsauvwdQjbs6HSNj9HAfNCqiHgkGW1AupAQywLNIAYGyx6OJxjYEJsxZKa7zhBwMjIn9duSPdhzWQW3XmiHUkKzAq0nIh_gaFA6jKKb1MOsaVjBY5MAthv-_HiQjkt7JV0I-D6JyY3Ch6QqevAbPMyvF23-M7pg8Gs-nEz35PvtxSB6DlxbOfY7I3mbV-Xdk311vLter970e_AFUL_nX |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pulmonary+Disease+Caused+by+Non-Tuberculous+Mycobacteria&rft.jtitle=Respiration&rft.au=Wassilew%2C+N&rft.au=Hoffmann%2C+H&rft.au=Andrejak%2C+C&rft.au=Lange%2C+C&rft.date=2016-01-01&rft.issn=0025-7931&rft.volume=91&rft.issue=5&rft.spage=386&rft_id=info:doi/10.1159%2F000445906&rft.externalDocID=oai_swepub_ki_se_505046 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0025-7931&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0025-7931&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0025-7931&client=summon |